Login / Signup

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test in Node-Negative Early Breast Cancer.

Vladislav BerdunovSteve MillenAndrew ParamoreJane GriffinSarah ReyniaNina FryerRebecca BrownLouise Longworth
Published in: ClinicoEconomics and outcomes research : CEOR (2022)
The analysis showed that the cost-effectiveness of the 21-gene assay is sensitive to assumptions for chemotherapy sparing for patients with RS 0-25 whose outcomes with endocrine therapy are no worse compared to chemotherapy-assigned patients, and a chemotherapy benefit in the RS 26-100 group. Future studies need to incorporate a wider set of tumour profiling tests other than the 21-gene assay to allow a direct comparison of their cost-effectiveness.
Keyphrases